Dr. Yomani Sarathkumara's research focuses on characterising humoral immune responses to Epstein-Barr virus (EBV) in EBV-associated diseases.

During her PhD at James Cook University, Australia, she identified novel antibody biomarkers for EBV-associated cancers, including natural killer/T-cell lymphoma and Hodgkin lymphoma, using well-characterised hospital-based case-control samples from the AsiaLymph study—a large, multicentre epidemiological investigation of lymphoma and related haematologic malignancies conducted across Asia in collaboration with the U.S. National Cancer Institute (NCI). She also identified antibody markers predictive of clinical responses in EBV-positive lymphoma patients treated with EBV-specific T-cell immunotherapy in Phase I clinical trials conducted by Baylor College of Medicine, USA.

Her Honours research at Northumbria University, UK, focused on identifying antibody responses to a fungal antigen associated with Pigeon Fancier's Lung disease. For her Master's by Research (MPhil) from 2016–2018, conducted in collaboration with the University of Peradeniya, Sri Lanka, and Hokkaido University, Japan, she demonstrated that hantavirus exposure is a major risk factor for developing chronic kidney disease of unknown aetiology (CKDu) in Sri Lanka—a significant public health concern in agricultural communities.

Following her PhD, Dr. Sarathkumara joined the University of Queensland (UQ) as a Postdoctoral Research Fellow under the supervision of Professor Denise Doolan. Building on her doctoral work, she is currently investigating the potential role of EBV in triggering autoimmune diseases such as multiple sclerosis (MS), aiming to identify diagnostic and predictive antibody biomarkers. This work is conducted in collaboration with the University of Texas and the Oklahoma Medical Research Foundation, USA. In parallel, she is also examining antibody responses in individuals with acute EBV infection through a collaboration with UMass Chan Medical School, University of Massachusetts, USA.

Her research integrates high-throughput serological profiling, statistical modelling, and immunoassay development, and is supported by strong international collaborations.